FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	------------------------------------------------------------------------------------------------------------------------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

			of Section So(n) of the investment company Act of 1940			
1. Name and Addr Patil Neena	1 0	Person*	2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]		ationship of Reporting Pe k all applicable) Director	erson(s) to Issuer 10% Owner
(Last) 5TH FL, WAT	(First) ERLOO EXCI	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2023	X	Officer (give title below) EVP & Chief Leg	Other (specify below) al Officer
WATERLOO I (Street) DUBLIN 4			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi ⁱ Line) X	vidual or Joint/Group Fili Form filed by One Rep Form filed by More tha Person	porting Person
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication			lan that is intended to

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Disposed O		ed (A) or str. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(IIISU: 4)	(1150.4)
Ordinary Shares	06/01/2023		S		1,526	D	\$127.9751 ⁽¹⁾	32,900 ⁽²⁾	D	
Ordinary Shares	06/01/2023		S		74	D	\$128.015	32,826	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.) PC	,	, .		,	optiono, c			•••••	-7			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Secu Acqu (A) o Dispo of (D	vative rities lired r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/N	ate	7. Titl Amou Secur Unde Deriv Secur (Instr	int of rities rlying ative	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from \$127.91 to \$128.015. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

2. Includes 87 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023.

By: /s/Adam Guttmann, as

attorney in fact For: Neena M 06/05/2023 Patil

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5